Sacubitril/valsartan in PARADIGM-HF Reply

被引：0

作者：

Seferovic, Jelena P. ^{[1
]}

Claggett, Brian ^{[1
]}

Solomon, Scott D. ^{[1
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA

来源：

LANCET DIABETES & ENDOCRINOLOGY | 2017年 / 5卷 / 07期

关键词：

HEART-FAILURE; ENALAPRIL;

D O I：

10.1016/S2213-8587(17)30179-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：496 / 496

页数：1

共 50 条

[31] Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Rosa Ahn
Vinay Prasad
Cardiovascular Drugs and Therapy, 2018, 32 : 637 - 637
[32] Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Jhund, Pardeep S.
Fu, Michael
Bayram, Edmundo
Chen, Chen-Huan
Negrusz-Kawecka, Marta
Rosenthal, Arvo
Desai, Akshay S.
Lefkowitz, Martin P.
Rizkala, Adel R.
Rouleau, Jean L.
Shi, Victor C.
Solomon, Scott D.
Swedberg, Karl
Zile, Michael R.
McMurray, John J. V.
Packer, Milton
EUROPEAN HEART JOURNAL, 2015, 36 (38) : 2576 - 2584
[33] Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF (vol 8, pg 800, 2020)
Docherty, K. F.
Vaduganathan, M.
Solomon, S. D.
McMurray, J. J., V
JACC-HEART FAILURE, 2020, 8 (12) : 1057 - 1057
[34] The clinical profile of a non-selected population treated with sacubitril/valsartan is different from PARADIGM-HF trial
Vicent Alaminos, L. Lourdes
Esteban Fernandez, A.
Gomez Bueno, M.
De Juan, J.
Diez Villanueva, P.
Iniesta, A. M.
Ayesta, A.
Gonzalez Saldivar, H.
Rojas, A.
Bover Freire, R.
Iglesias, D.
Garcia Aguado, M.
Perea Egido, J. A.
Martinez-Selles, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 9 - 9
[35] Generalizability Of The Paradigm-HF Trial For The Use Of Sacubitril/Valsartan In A Tertiary Care Outpatient Heart Failure Patient Population
Sackheim, Julia
Chan, Doris
Beers, Kelly
Khan, Hassan
Papadimitriou, Lampros
Bloom, Michelle W.
Butler, Javed
Skopicki, Hal
CIRCULATION, 2016, 134
[36] Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
Sokos, George G.
Raina, Amresh
VASCULAR HEALTH AND RISK MANAGEMENT, 2020, 16 : 41 - 51
[37] Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study
Shi, Victor
Senni, Michele
Streefkerk, Hendrik
Modgill, Vikas
Zhou, Wenchun
Kaplan, Allen
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 264 : 118 - 123
[38] Outcomes in patients with and without atrial fibrillation in PARADIGM-HF and effect of sacubitril/valsartan according to atrial fibrillation status
Mogensen, U.
Swedberg, K.
Kober, L.
Jhund, P.
Shi, V. C.
Rouleau, J. L.
Solomon, S. D.
Zile, M. R.
Packer, M.
McMurray, J. J. V.
EUROPEAN HEART JOURNAL, 2016, 37 : 193 - 193
[39] Sacubitril-valsartan in patients with NT-proBNP levels outrange of PARADIGM-HF trial inclusion criteria
Mario Galvan Ruiz, M.
Fernandez De Sanmamed Giron, M.
Singh, M.
Groba Marco, M. V.
Davila Ramos, M.
Lopez Perez, M.
Hernandez Meneses, B.
Godoy Camacho, C.
Martin Lorenzo, P.
Cardenes Leon, A.
Bujanda Morun, P.
Perez Nogales, E. D.
Medina Gil, J. M.
Caballero Dorta, E.
Garcia Quintana, A.
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 112 - 113
[40] Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis
Rohde, Luis E.
Claggett, Brian L.
Wolsk, Emil
Packer, Milton
Zile, Michael
Swedberg, Karl
Rouleau, Jean
Pfeffer, Marc A.
Desai, Akshay S.
Lund, Lars H.
Kober, Lars
Anand, Inder
Merkely, Bela
Senni, Michele
Shi, Victor
Rizkala, Adel
Lefkowitz, Martin
McMurray, John J., V
Solomon, Scott D.
CIRCULATION-HEART FAILURE, 2021, 14 (03) : 361 - 371

← 1 2 3 4 5 →